Previous close | 0.4070 |
Open | 0.4045 |
Bid | 0.2800 x 200 |
Ask | 0.5649 x 200 |
Day's range | 0.4001 - 0.4357 |
52-week range | 0.3000 - 1.3500 |
Volume | |
Avg. volume | 207,562 |
Market cap | 7.356M |
Beta (5Y monthly) | 1.11 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.1600 |
Earnings date | 12 Aug 2024 - 16 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.00 |
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK study with optimized formulation of TRV045 advances, with data expected 2H 2024 CHESTERBROOK, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results f
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has closed its previously announced offering for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,77